Childhood Cancer Research

You are here

Children’s Hospital of Philadelphia

3401 Civic Center Boulevard

Philadelphia, PA 19104

United States

Center of Excellence in Childhood Cancer Drug Development and Clinical Pharmacology at CHOP

General Pediatric Cancer

Developing new therapies for infants, children, adolescents and young adults with cancer requires a well-trained, dedicated multidisciplinary team. Physicians and scientists at The Children's Hospital of Philadelphia Division of Oncology and Center for Childhood Cancer Research are collaborating to develop new therapies for cancer. We are dedicated to improving our understanding of the biology and genomics of childhood cancer, developing better preclinical models, evaluating new drugs, and improving the efficiency and conduct of clinical trials.

Christina Turn

Children’s Hospital of Philadelphia

Nathan Singh, MD

Children’s Hospital of Philadelphia

Sarah Tasian, MD

Children’s Hospital of Philadelphia

Jacquelyn Crane, MD

Children’s Hospital of Philadelphia

Ted Laetsch, MD

Children’s Hospital of Philadelphia

Frank Balis, MD

Children’s Hospital of Philadelphia

Rachel Hurley, MD/PhD

Children’s Hospital of Philadelphia

Adeline Yang, MD

Children’s Hospital of Philadelphia

Characterizing the role of measurable residual disease (MRD) in pediatric acute myeloid leukemia (AML) survival disparities

Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is a rare but very serious type of blood cancer in children. While treatments for childhood cancer have improved, 20-40% of children of AML still do not survive. Black and Hispanic children are less likely to survive than White children, which may be due to differences in access to care, delays in getting diagnosed, or other barriers that disproportionately affect families from minority communities. Black and Hispanic children are also less likely to be enrolled on clinical trials, but children on clinical trials do better. We don’t know why.

Pages